Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ensovibep  COVID-19 treatment studies for Ensovibep  C19 studies: Ensovibep  Ensovibep   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
 
    
  
Ensovibep for COVID-19
2 studies from 81 scientists
Statistically significant improvement for hospitalization.
One study shows statistically significant improvement in isolation.
COVID-19 Ensovibep studies. Dec 2022. c19early.org/ev
0 0.5 1 1.5+ All studies 46% Mortality 46% Hospitalization 87% RCTs 46% RCT mortality 46% Early 89% Late 17% Favorsensovibep Favorscontrol
Ensovibep COVID-19 studies. Ensovibep requires IV infusion, but may be less variant dependent than monoclonal antibodies. Recent:
Barkauskas.
Submit updates/corrections.
Dec 2
Covid Analysis (Preprint) (meta analysis) Ensovibep for COVID-19: real-time meta analysis of 2 studies
Statistically significant improvement is seen for hospitalization. One study shows statistically significant improvement in isolation (not for the most serious outcome). • Meta analysis using the most serious outcome reported shows..
Aug 9
Barkauskas et al., Annals of Internal Medicine, doi:10.7326/M22-1503 Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
17% lower mortality [p=0.46], 6% improved recovery [p=0.55], and 7% higher hospital discharge [p=0.46]. RCT 485 hospitalized patients showing no significant differences with ensovibep treatment. Intravenous ensovibep, 600mg.
Jan 10
Novartis Press Release (News) Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
89% lower mortality [p=0.06], 87% lower hospitalization [p=0.01], and 78% fewer combined hospitalization/ER visits [p=0.02]. EMPATHY Part A RCT with 407 patients, 301 treated with ensovibep, showing statistically significant viral load reduction (details not provided), and lower mortality and hospitalization. For discussion see [twitter.com].
Nov 16
2021
Molecular Partners, Press Release (News) Molecular partners provides update from ACTIVE-3 global clinical study of ensovibep in patients hospitalized with COVID-19
no change in recovery [p=1]. News release reporting that ensovibep was terminated for futility in ACTIV-3. 470 patients had been randomized.
Feb 3
2021
Rothenberger et al., bioRxiv, doi:10.1101/2021.02.03.429164 (Preprint) (In Vitro) Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants
In Silico, In Vitro, and hamster study of ensovibep, a DARPin candidate that can engage all three units of the spike protein trimer to inhibit ACE2 interaction, showing efficacy for common variants, and efficacy comparable to casirivimab/..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit